News

Synthon’s three-times-a-week glatiramer acetate is a therapeutically equivalent version of the originator medicine Copaxone®* 40mg.  Synthon received regulatory clearance in all 27 EU/EEA member states involved in the

The study is assessing the efficacy and safety of anticoagulant medicine for the secondary prevention of stroke and systemic embolism in patients with a recent embolic stroke of

The FDA’s orphan designation is granted to encourage the development of potential products for rare conditions that affect less than 200,000 patients annually in the US. cGVHD is

The company raised an initial $23.1 million in June 2016. The extension of the Series C supports Visterra’s focus on its two lead product candidates, VIS410 and VIS649,

This landmark research is a collaboration between Anthem, Inc., its outcomes research subsidiary, HealthCore, Inc. and Boehringer Ingelheim, a pharmaceutical company with a long history of leadership in

The Zika vaccine showed both safety and the ability to induce high levels of antibodies in all the 40 participants of the trial against the mosquito-borne virus in

Under the terms of the agreement, Ligand will pay Crystal shareholders $25 million in cash at closing, up to an additional $10.5 million of success-based milestones, and revenue

Iclaprim, which is a diaminopyrimidine antibiotic, met its primary endpoint and was found to be well tolerated during the phase 3 clinical trial dubbed REVIVE-2. Featuring 600 ABSSSI

The over-subscribed round brings the company's total capital raised to more than $80 million. Recursion augments traditional drug discovery approaches, most prominently phenotypic screening, with artificial intelligence (AI).